Ginkgo ( DrugBank: Ginkgo )

5 diseases

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01416818 (ClinicalTrials.gov)	May 2008	11/8/2011	Treatment of Depression in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled Study of Xiaoyao Pill Treatment of Depression in Patients With Parkinson's Disease	Depression in Parkinson's Disease	Drug: Xiaoyao Pill;Drug: Bupleurum+Ginkgo;Drug: placebo	Xuanwu Hospital, Beijing	NULL	Recruiting	30 Years	80 Years	Both	60	Phase 2	China

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00841321 (ClinicalTrials.gov)	January 2009	9/2/2009	Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis	Ginkgo Biloba for Cognitive Impairment in Multiple Sclerosis	Multiple Sclerosis;Cognitive Ability, General	Drug: Ginkgo biloba;Drug: Placebo	VA Office of Research and Development	NULL	Completed	18 Years	65 Years	All	120	Phase 2	United States
2	NCT00010842 (ClinicalTrials.gov)	September 1999	2/2/2001	Natural Antioxidants in the Treatment of Multiple Sclerosis	Natural Antioxidants in the Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: Ginkgo biloba;Drug: Alpha-lipoic acid;Drug: Vitamin E/Selenium;Drug: Essential fatty acids	National Center for Complementary and Integrative Health (NCCIH)	NULL	Completed	N/A	N/A	Both		Phase 1/Phase 2	United States

臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-005371-34-FR (EUCTR)	18/03/2008	20/12/2007	EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIAA 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study. - EGB 761 in FRIEDREICH ATAXIA	EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIAA 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study. - EGB 761 in FRIEDREICH ATAXIA	Out patient suffering from friedreich ataxia aged from 12 to 20 years	Trade Name: Rokan (r) Novo 120 mg Product Name: EGB 761 (r) 120 mg INN or Proposed INN: Standardized Ginkgo Biloba Extract (EGb 761 (r)	BEAUFOUR IPSEN PHARMA	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 2	France

臨床試験数 : 9 / 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 16

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100048104	2021-08-01	2021-07-01	A clinical study of safety and efficacy of transcatheter intra-arterial infusion of extract of Ginkgo biloba leaves injection in the treatment of sever limb ischemia in patients with Thromboangiitis Obliterans	A clinical study of safety and efficacy of transcatheter intra-arterial infusion of extract of Ginkgo biloba leaves injection in the treatment of sever limb ischemia in patients with Thromboangiitis Obliterans	Thromboangiitis Obliterans	Treatment group:Transcatheter intra-arterial infusion of Ginkgo biloba leaves injection;Control group:Transcatheter intra-arterial infusion of heparin sodium injection;	First Clinical Center of Chinese PLA General Hospital	NULL	Pending		50	Both	Treatment group:30;Control group:30;		China

臨床試験数 : 147 / 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02465749 (ClinicalTrials.gov)	May 2015	22/5/2015	Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa	Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa	Retinitis Pigmentosa	Drug: Continuous oxygen;Device: blue light-absorbing sunglasses;Drug: Compound thrombosis capsule sig: 1.5g/tid;Drug: Ginkgo biloba pills sig: 300mg/tid;Drug: Vitamin B sig: 10mg/tid;Drug: Vitamin AD sig: 1 tablet/tid	Sun Yat-sen University	Zhujiang Hospital;Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;Guangzhou Jeeyor Medical Research Co.,Ltd.	Not yet recruiting	18 Years	60 Years	Both	404	Phase 0	China